Results 131 to 140 of about 290,024 (350)

Long‐term immunosuppression for CNS mouse xenotransplantation: Effects on nigrostriatal neurodegeneration and neuroprotective carotid body cell therapy [PDF]

, 2018
Javier Villadiego, Sonia Romo‐Madero, Roberto García‐Swinburn, Nela Suárez‐Luna, Alfonso Bermejo‐Navas, Miriam Echevarrı́a, Juan José Toledo‐Aral   +6 more
openalex   +1 more source

Efferocytosis‐Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer

Advanced Science, EarlyView.
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Wenhan Li, Feiquan Ying, Xinkai Pang, Qiulei Wu, Guoqing Li, Lin Huang, Jiayu Xin, Xiaoli Liu, Pan Liu, Xiaohan Xu, Shuran Tan, Yumei Gao, Tong Liu, Si Sun, Xiaoman Wang, Yiping Wen, Liqiong Cai, Shi Du, Yuan Zhang, Jing Cai   +19 more
wiley   +1 more source

Successful thrombolytic therapy is associated with increased granulocyte CD15 expression and reduced stroke‐induced immunosuppression [PDF]

, 2022
Katalin Anna Béres‐Molnár, Ágnes Czeti, Ferenc Takács, Gábor Barna, Dániel Péter Kis, Gabriella Róka, András Folyovich, Gergely Toldi   +7 more
openalex   +1 more source

METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation

Advanced Science, EarlyView.
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li, Xiao Zhao, Tongtong Song, Qiaoyi Chen, Yanqing Wu, Yuting Zhang, Jingying Chen, Yifan Wu, Bin Li, Xinyue Zhang, Zihao Dai, Lixia Xu, Yubin Xie, Alfred Sze‐Lok Cheng, Jianping Guo, Ming Kuang, Shuibin Lin, Zhenwei Peng, Sui Peng, Xuezhen Zeng   +19 more
wiley   +1 more source

A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines

Advanced Science, EarlyView.
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin, Chenchen Zhang, Jiahao Li, Kun Huang, Min Qiu   +4 more
wiley   +1 more source

Therapy Code List - Immunosuppression Aurum Therapy Codes

, 2020
Harriet Forbes
openalex   +1 more source

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

Advanced Science, EarlyView.
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu, Muhammad Aminu, Pingjun Chen, Jian‐Rong Li, Chuanpeng Dong, Chenyang Li, Yanhua Tian, Shao‐Wei Lu, Hong Chen, Chenxi Ma, Xin Hu, Jie Ye, Andrew Y. Liu, Beibei Huang, Frank R. Rojas, Parra Cuentas. Edwin Roger, Ou Shi, Monique B. Nilsson, Alissa Poteete, Khaja B. Khan, Wei Lu, Luisa M. Solis Soto, Junya Fujimoto, Cara Haymaker, Ignacio I. Wistuba, Zhubo Wei, Linghua Wang, Don L. Gibbons, Ken Chen, Alexandre Reuben, Jason M. Schenkel, John V. Heymach, Chao Cheng, Jia Wu, Jianjun Zhang   +34 more
wiley   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. [PDF]

EBioMedicine, 2020
Chen T, Xia E, Chen T, Zeng C, Liang S, Xu F, Qin Y, Li X, Zhang Y, Liang D, Xie G, Liu Z.   +11 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source